Speculation Grows On Potential Big Pharma Buyout Of Mirati
Deal Could Hinge On New Readouts
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.
You may also be interested in...
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.